Literature DB >> 13891386

Treatment of toxoplasmosis uveitis.

R V FAJARDO, F P FURGIUELE, I H LEOPOLD.   

Abstract

Entities:  

Keywords:  TOXOPLASMOSIS/complications; UVEITIS/therapy

Mesh：

Year:  1962        PMID： 13891386     DOI： 10.1001/archopht.1962.00960020712004

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  8 in total

1.  Spiramycin for Toxoplasmosis.

Authors:  J V Cassady; J W Bahler; M V Hinken
Journal:  Trans Am Ophthalmol Soc       Date:  1963

2.  Clinical manifestation and prognosis of active ocular toxoplasmosis in Iran.

Authors:  Farzan Kianersi; Afsaneh Naderi Beni; Zahra Naderi Beni
Journal:  Int Ophthalmol       Date:  2012-06-26       Impact factor: 2.031

3.  Treatment of active toxoplasmic retino-choroiditis.

Authors:  J Nolan; E S Rosen
Journal:  Br J Ophthalmol       Date:  1968-05       Impact factor: 4.638

4.  Ocular toxoplasmosis in AIDS patients.

Authors:  D J Gagliuso; S A Teich; A H Friedman; J Orellana
Journal:  Trans Am Ophthalmol Soc       Date:  1990

5.  [Diagnosis and treatment of ocular toxoplasmosis : a survey of German-speaking ophthalmologists].

Authors:  N Torun; Z Sherif; J Garweg; U Pleyer
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

Review 6.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

7.  A prospective randomized trial of azithromycin versus trimethoprim/sulfamethoxazole in treatment of toxoplasmic retinochoroiditis.

Authors:  Alireza Lashay; Ahmad Mirshahi; Najaf Parandin; Hamid Riazi Esfahani; Mehdi Mazloumi; Mohammad Reza Lashay; Mohammad Karim Johari; Elham Ashrafi
Journal:  J Curr Ophthalmol       Date:  2016-12-28

Review 8.  Current treatment of toxoplasma retinochoroiditis: an evidence-based review.

Authors:  Meredith Harrell; Petros E Carvounis
Journal:  J Ophthalmol       Date:  2014-08-13       Impact factor: 1.909
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.